A Lawyer Breaks Down the Legal Reality of Peptides
The peptide market exists in a legal gray zone that confuses just about everyone involved, including patients, physicians, and sometimes the regulators themselves. This video from Holt Law, a firm that advises healthcare providers and supplement companies on FDA regulations, walks through the actual legal framework governing peptide sales, prescribing, and use in the United States. If you have been confused about what is legal, what is not, and what might change, this is a good place to start getting clarity.
The fundamental issue is that most peptides used for therapeutic purposes (BPC-157, CJC-1295, Ipamorelin, TB-500, and others) are not FDA-approved drugs. They have not gone through the New Drug Application (NDA) process, which means no pharmaceutical company has submitted the required clinical trial data proving their safety and efficacy to the FDA's satisfaction. That does not make them illegal by default, but it places them in a regulatory category that is complicated and evolving.
To understand the legal landscape, you need to understand three different pathways through which peptides reach consumers: compounding pharmacies, research chemical suppliers, and dietary supplement companies. Each pathway has its own legal rules, risks, and levels of regulatory oversight. Holt Law examines all three, and the distinctions matter more than most people realize for both legal protection and product safety.
Compounding Pharmacies: The Most Legitimate Pathway
The primary legal pathway for accessing therapeutic peptides is through a licensed compounding pharmacy with a valid prescription from a licensed physician. Under federal law (the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013), compounding pharmacies can prepare medications that are not commercially available when a patient has a specific medical need identified by their doctor.
There are two types of compounding pharmacies, and the difference between them matters. Section 503A pharmacies compound individual prescriptions based on a doctor-patient relationship. Section 503B outsourcing facilities can produce larger batches and are registered with and inspected by the FDA. For peptides specifically, 503B facilities generally provide higher quality assurance because they are held to current Good Manufacturing Practice (cGMP) standards and undergo regular federal inspections.
The legal catch is that compounding pharmacies can only use "bulk drug substances" that meet certain criteria. The FDA maintains a list of substances that are eligible for compounding and, critically, a list of substances that are NOT eligible. In late 2023 and into 2024, the FDA took action against several peptides that had been widely available through compounding pharmacies. BPC-157, for example, was placed on the FDA's list of substances under review, creating uncertainty about its future availability from legitimate compounding sources.
Holt Law explains that this is an ongoing regulatory process, not a final determination. The FDA can propose adding substances to the "cannot compound" list, but that proposal goes through a public comment period and is subject to legal challenge. Several peptide advocacy groups and compounding pharmacy associations have submitted formal comments arguing that peptides like BPC-157 should remain available for compounding. The outcome of this process will determine the legal landscape for the next several years at minimum.
Research Chemical Suppliers: The Gray Market
The second pathway is research chemical suppliers, often called "peptide research companies." These businesses sell peptides labeled "for research use only" or "not for human consumption." The legal theory is that selling a chemical compound for legitimate research purposes is legal, and the buyer assumes responsibility for how the product is used.
In practice, everyone in the industry knows that many buyers are purchasing these peptides for personal use, not for academic or clinical research. Holt Law does not sugarcoat this: the "for research only" label is a legal fiction that provides some cover for the seller but virtually no protection for the buyer. If the FDA wanted to pursue individual consumers for buying research peptides for personal injection, they could theoretically do so, though enforcement at the individual level has been extremely rare.
The bigger risk for consumers is product quality. Research chemical suppliers are not required to follow pharmaceutical manufacturing standards. They are not inspected by the FDA. Their products do not need to pass sterility testing, endotoxin testing, or potency verification. Some suppliers do voluntarily test their products and publish certificates of analysis, but there is no regulatory requirement to do so, and the testing itself is often self-reported rather than independently verified.
Holt Law advises that if you are going to use research-grade peptides (which they note they are not recommending), you should at minimum verify that the supplier provides third-party tested COAs from an accredited lab. But they also note that even with a COA, the legal and safety protections are minimal compared to obtaining the same peptide through a licensed compounding pharmacy with a valid prescription.
Dietary Supplements: Where the Claims Get Sketchy
The third pathway is the dietary supplement market, where some companies sell oral peptide products under the Dietary Supplement Health and Education Act (DSHEA). This law allows companies to sell products containing dietary ingredients (including amino acids and protein-derived compounds) without FDA pre-approval, as long as they do not make specific drug claims.
The problem is that many peptide supplement companies are making claims that cross the line from supplement claims into drug claims. Saying a product "supports joint health" is a legal supplement claim (called a structure/function claim). Saying a product "heals tendon injuries" or "accelerates recovery from surgery" is a drug claim that requires FDA approval. The FDA has sent warning letters to numerous peptide supplement companies for making unauthorized drug claims, and some of these actions have resulted in product seizures and injunctions.
There is also a bioavailability question with oral peptide supplements. Most peptides are digested in the stomach and intestines before they can reach the bloodstream in active form. Some companies claim to use special delivery technologies (enteric coatings, liposomal encapsulation, nano-emulsions) to protect the peptide from digestion, but the evidence for these delivery systems is often limited or proprietary. Holt Law points out that the supplement pathway may be the most legally accessible but also the most questionable in terms of whether the product actually delivers a biologically active peptide to the target tissue.
What the FDA Is Likely to Do Next
Holt Law offers some informed speculation about where regulatory trends are heading. The FDA has been increasing enforcement against both compounding pharmacies and research chemical suppliers that are providing peptides for human therapeutic use. The agency appears to be moving toward a framework where most therapeutic peptides will either need to go through the full NDA approval process or be restricted from compounding.
There are counterforces pushing back. The compounding pharmacy industry has significant lobbying power, and there is growing bipartisan political interest in preserving patient access to compounded medications, particularly after the GLP-1 shortage highlighted how dependent patients are on pharmaceutical supply chains. Several members of Congress have introduced legislation that would protect compounding access for specific categories of medications, though none of these bills have passed as of early 2026.
The most likely outcome, according to Holt Law, is a middle ground where some peptides remain available through compounding with increased regulatory oversight, while others are restricted pending further study. BPC-157, given its widespread use and relatively favorable safety data, is considered more likely to survive the regulatory review than some of the newer and less-studied peptides.
Protecting Yourself in the Current Environment
If you are currently using peptides or considering starting, the most legally and medically defensible approach is to work with a licensed physician who prescribes the peptide and a licensed compounding pharmacy (preferably a 503B outsourcing facility) that fills the prescription. This creates a documented medical relationship, a valid prescription, and a product from a regulated source. If any regulatory questions arise, you have a clear paper trail showing legitimate medical use.
Keep records of your prescriptions, your pharmacy receipts, and any lab work related to your peptide use. If the regulatory landscape shifts and certain peptides become restricted, having documentation of established medical use may provide some protection during transition periods. This is not guaranteed, but it is better than having no documentation at all.
Stay informed about FDA actions related to the specific peptides you use. The FDA's website publishes compounding-related guidance documents, warning letters, and updated lists of substances eligible for compounding. Holt Law recommends checking these resources quarterly, or following an industry trade group that tracks regulatory changes and sends alerts to members. The legal landscape for peptides is changing faster than most people realize, and staying current on the rules is part of using these compounds responsibly. What was legal six months ago may not be legal today, and what is legal today may change in the coming months.
The legal complexity of the peptide market is not a reason to avoid it entirely. It is a reason to approach it with your eyes open, with professional guidance, and with the understanding that this is a fast-moving regulatory environment that rewards informed and cautious participation over blind trust in any single source or seller.